Examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke: A systematic review of pre-clinical and clinical studies
Background: Blood pressure control is one of the basic steps in preventing stroke and cerebrovascular events. Calcium channel blockers are the first-line drugs in hypertension control. On the other hand, the stroke recovery phase depends on activating calcium channels and N-methyl-D-aspartate (NMDA)...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | IBRO Neuroscience Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266724212500003X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586191769174016 |
|---|---|
| author | Sevak Hatamian Asad Abdi Fatemeh Sadat Seyedi Asl Armin Tafazolimoghadam Arian Tavasol Seyed Ali Mousavi Nejad Reza Madadi Zohre Tajabadi Mina Dehghani Najmeh Ahmadpoor Mobina Fathi Mohammadreza Hajiesmaeili Navid Nooraei |
| author_facet | Sevak Hatamian Asad Abdi Fatemeh Sadat Seyedi Asl Armin Tafazolimoghadam Arian Tavasol Seyed Ali Mousavi Nejad Reza Madadi Zohre Tajabadi Mina Dehghani Najmeh Ahmadpoor Mobina Fathi Mohammadreza Hajiesmaeili Navid Nooraei |
| author_sort | Sevak Hatamian |
| collection | DOAJ |
| description | Background: Blood pressure control is one of the basic steps in preventing stroke and cerebrovascular events. Calcium channel blockers are the first-line drugs in hypertension control. On the other hand, the stroke recovery phase depends on activating calcium channels and N-methyl-D-aspartate (NMDA) receptors. Considering these issues, one of the interdisciplinary challenges of neurology and cardiology is the use of these drugs in hypertensive patients with cerebrovascular accident (CVA) risk and their uses after these events. Objectives: This study's primary goal is to evaluate the effects of calcium channel blockers on reducing the risk, mortality, morbidity, and long-term outcomes of cerebrovascular events. Material and Methods: We conducted this systematic literature review by searching PubMed, Scopus, and Google Scholar databases. Our inclusion criteria were randomized clinical trials, cohort studies, case-cross-over studies, case reports, and in-vitro and animal studies in which they evaluated the effects of calcium channel blockers on the CVA risk and mortality, morbidity, and long-term outcomes of stroke. Our exclusion criteria were review studies with no adequate data and non-English articles. Articles that met our criteria were included in the initial search. After the title and abstract screening, 56 human and animal studies were selected to be discussed in this article. Results: Among 56 selected studies, 33 were human studies, 23 were animal experiments, and one study was carried out both on animals and humans. A total of 1,860,234 patients were enrolled in 24 human studies. A total of 717,131 patients in 22 studies received CCBs. Two studies did not report the number of patients who underwent treatment with CCBs. Among 24 studies, 11 reported favorable outcomes following CCB administration, and two studies reported neuroprotective effects for CCBs without any adverse outcome in stroke patients. Five studies demonstrated that CCBs were associated with adverse outcomes. One study showed favorable and unfavorable outcomes compared to other antihypertensive agents. Stroke was reported in two studies following CCB overdose. Three studies have reported that CCBs had no significant effect on stroke risk, mortality, or long-term outcomes. In animal studies, a total of 813 animals were enrolled in 19 studies. Two studies were in vitro using mammalian cells and enzymes, and one study was ex-vivo. Among 24 studies, 18 (75 %) reported beneficial outcomes following treatment with CCBs, three (12.5 %) revealed both favorable and unfavorable results, two (8.3 %) demonstrated adverse outcomes, and one (4.2 %) showed no effect. Conclusion: Based on the evidence from human and animal studies, authors conclude that CCBs are associated with a lower risk of stroke, lower mortality risk, and improved long-term neurological and other clinical outcomes. |
| format | Article |
| id | doaj-art-467b25d9db474793894fe1e091ea8863 |
| institution | Kabale University |
| issn | 2667-2421 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | IBRO Neuroscience Reports |
| spelling | doaj-art-467b25d9db474793894fe1e091ea88632025-01-26T05:05:18ZengElsevierIBRO Neuroscience Reports2667-24212025-06-0118222243Examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke: A systematic review of pre-clinical and clinical studiesSevak Hatamian0Asad Abdi1Fatemeh Sadat Seyedi Asl2Armin Tafazolimoghadam3Arian Tavasol4Seyed Ali Mousavi Nejad5Reza Madadi6Zohre Tajabadi7Mina Dehghani8Najmeh Ahmadpoor9Mobina Fathi10Mohammadreza Hajiesmaeili11Navid Nooraei12FCCM, Department of Anaesthesia, Clinical Research Development Unit of Shahid Madani Hospital, School of Medicine, Alborz University of Medical Sciences, Karaj, IranDepartment of Neurology, MIRDIF Hospital Dubai, United Arab Emirates; Department of Neurology, Iranian Hospital Dubai, United Arab EmiratesSchool of Medicine, Tehran University of Medical Science (TUMS), Tehran, IranSchool of Medicine, Tehran University of Medical Science (TUMS), Tehran, IranStudent Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Cardiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, IranStudent Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranSchool of Medicine, Isfahan University of Medical Sciences, Isfahan, IranStudent Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranStudent Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranAnesthesia and Critical Care Department, Critical Care Quality Improvement Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Correspondence to: Critical Care Medicine, Critical Care Quality Improvement Research Center, Loqman Hakim Hospital, Hor Street, Tehran, IranCritical Care Quality Improvement Research Center, Shahid Modarres Hospital, and Department of Anesthesiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Corresponding author.Background: Blood pressure control is one of the basic steps in preventing stroke and cerebrovascular events. Calcium channel blockers are the first-line drugs in hypertension control. On the other hand, the stroke recovery phase depends on activating calcium channels and N-methyl-D-aspartate (NMDA) receptors. Considering these issues, one of the interdisciplinary challenges of neurology and cardiology is the use of these drugs in hypertensive patients with cerebrovascular accident (CVA) risk and their uses after these events. Objectives: This study's primary goal is to evaluate the effects of calcium channel blockers on reducing the risk, mortality, morbidity, and long-term outcomes of cerebrovascular events. Material and Methods: We conducted this systematic literature review by searching PubMed, Scopus, and Google Scholar databases. Our inclusion criteria were randomized clinical trials, cohort studies, case-cross-over studies, case reports, and in-vitro and animal studies in which they evaluated the effects of calcium channel blockers on the CVA risk and mortality, morbidity, and long-term outcomes of stroke. Our exclusion criteria were review studies with no adequate data and non-English articles. Articles that met our criteria were included in the initial search. After the title and abstract screening, 56 human and animal studies were selected to be discussed in this article. Results: Among 56 selected studies, 33 were human studies, 23 were animal experiments, and one study was carried out both on animals and humans. A total of 1,860,234 patients were enrolled in 24 human studies. A total of 717,131 patients in 22 studies received CCBs. Two studies did not report the number of patients who underwent treatment with CCBs. Among 24 studies, 11 reported favorable outcomes following CCB administration, and two studies reported neuroprotective effects for CCBs without any adverse outcome in stroke patients. Five studies demonstrated that CCBs were associated with adverse outcomes. One study showed favorable and unfavorable outcomes compared to other antihypertensive agents. Stroke was reported in two studies following CCB overdose. Three studies have reported that CCBs had no significant effect on stroke risk, mortality, or long-term outcomes. In animal studies, a total of 813 animals were enrolled in 19 studies. Two studies were in vitro using mammalian cells and enzymes, and one study was ex-vivo. Among 24 studies, 18 (75 %) reported beneficial outcomes following treatment with CCBs, three (12.5 %) revealed both favorable and unfavorable results, two (8.3 %) demonstrated adverse outcomes, and one (4.2 %) showed no effect. Conclusion: Based on the evidence from human and animal studies, authors conclude that CCBs are associated with a lower risk of stroke, lower mortality risk, and improved long-term neurological and other clinical outcomes.http://www.sciencedirect.com/science/article/pii/S266724212500003XCalcium channel blockerStrokeCerebrovascular accident |
| spellingShingle | Sevak Hatamian Asad Abdi Fatemeh Sadat Seyedi Asl Armin Tafazolimoghadam Arian Tavasol Seyed Ali Mousavi Nejad Reza Madadi Zohre Tajabadi Mina Dehghani Najmeh Ahmadpoor Mobina Fathi Mohammadreza Hajiesmaeili Navid Nooraei Examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke: A systematic review of pre-clinical and clinical studies IBRO Neuroscience Reports Calcium channel blocker Stroke Cerebrovascular accident |
| title | Examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke: A systematic review of pre-clinical and clinical studies |
| title_full | Examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke: A systematic review of pre-clinical and clinical studies |
| title_fullStr | Examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke: A systematic review of pre-clinical and clinical studies |
| title_full_unstemmed | Examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke: A systematic review of pre-clinical and clinical studies |
| title_short | Examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke: A systematic review of pre-clinical and clinical studies |
| title_sort | examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke a systematic review of pre clinical and clinical studies |
| topic | Calcium channel blocker Stroke Cerebrovascular accident |
| url | http://www.sciencedirect.com/science/article/pii/S266724212500003X |
| work_keys_str_mv | AT sevakhatamian examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT asadabdi examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT fatemehsadatseyediasl examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT armintafazolimoghadam examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT ariantavasol examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT seyedalimousavinejad examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT rezamadadi examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT zohretajabadi examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT minadehghani examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT najmehahmadpoor examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT mobinafathi examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT mohammadrezahajiesmaeili examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies AT navidnooraei examiningthetherapeuticpotentialandsideeffectsofcalciumchannelblockersinmortalityandmorbidityofpatientswithstrokeasystematicreviewofpreclinicalandclinicalstudies |